← Eichor
Condition: Amplification Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Amplification

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Effect of Mild-gain Amplification on Tinnitus Perception in Normal Hearing Adults
NA · 1 location(s) · Technical University of Denmark · NCT07489807The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT04403867The Swedish BioFINDER Sleep Study
Phase N/A · 1 location(s) · Skane University Hospital · NCT07533799Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unre
Phase 1/Phase 2 · 1 location(s) · Liu Huang · NCT06980532Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Phase 2 · 16 location(s) · Tyra Biosciences, Inc · NCT07265947A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Phase 1/Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT06343064A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Phase 1 · 15 location(s) · Nuvectis Pharma, Inc. · NCT05873686Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT06574347Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Phase 1/Phase 2 · 42 location(s) · ORIC Pharmaceuticals · NCT05315700ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Ad
Phase 2 · 37 location(s) · AbbVie · NCT07196644Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 44 location(s) · Haihe Biopharma Co., Ltd. · NCT04270591Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-posi
Phase 3 · 185 location(s) · Jazz Pharmaceuticals · NCT06282575Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Blad
Phase 2 · 46 location(s) · Tyra Biosciences, Inc · NCT06995677A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doubl
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06829459DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adul
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05786716Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06947291Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Avenzo Therapeutics, Inc. · NCT05867251A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTR
Phase 1/Phase 2 · 6 location(s) · Cullgen (Shanghai),Inc · NCT07394374Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins
Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT03310879Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
Phase N/A · 2 location(s) · Tianjin Medical University · NCT07618936Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Ot
Phase 1/Phase 2 · 33 location(s) · Novartis Pharmaceuticals · NCT06726148Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813456A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 19 location(s) · NiKang Therapeutics, Inc. · NCT06586957Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
NA · 1 location(s) · Michigan State University · NCT07599696Movement Amplification Gait Training to Enhance Walking Balance Post-Stroke
NA · 2 location(s) · VA Office of Research and Development · NCT06400186MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
Phase 1 · 3 location(s) · Eilean Therapeutics · NCT07524140
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.